Strive CEO Matthew Ryan Cole bought 515,195 shares of ASST at $0.81 each for $415,999, with ASST trading up as much as $0.89 intraday and the stock up about 9.8% on Tuesday; Cole’s purchase was roughly a 10.8% paper gain at the session high. At Vera Therapeutics, insider Patrick G. Enright bought 5,882 shares at $42.50 each for $249,985 (he previously bought 5.28M shares at $21.11 apiece within the past year); VERA reached $49.77 intraday but was down about 1% on Tuesday. These contemporaneous insider purchases signal management conviction, though market responses were mixed.
Strive's CEO Matthew Ryan Cole purchased 515,195 shares of ASST at $0.81 each for $415,999, and ASST traded up about 9.8% on Tuesday with an intraday high of $0.89, implying a roughly 10.8% paper gain at the session high. This is a clear, contemporaneous insider buy that coincided with a strong intraday market response and a higher per-ticker sentiment score for ASST (0.6). At Vera Therapeutics, Patrick G. Enright bought 5,882 shares at $42.50 totaling $249,985; he previously purchased 5.28M shares at $21.11 each within the past year. VERA reached $49.77 intraday but was trading down about 1% on Tuesday, producing a roughly 17.1% paper gain at the session high for Enright and a lower per-ticker sentiment score (0.3). Insider activity signals management conviction for both names but market reaction was mixed and the overall market_impact_score is low (0.3), indicating limited broader-market implications. Investors should treat these as company-specific signals and monitor Form 4 filings, follow-through volume and subsequent insider activity before changing material position sizes given the modest absolute dollar amounts and divergent intraday price behavior.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
